Trial reportBMC cardiovascular disorders2012
Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan.
Trial report in BMC cardiovascular disorders, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01447550 (Treatment of Thromboangiitis Obliterans), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Thromboangiitis Obliterans (Buerger's Disease) With Bosentan
Who cites it
9 citing papers in PubMed, 37 citations in OpenAlex.
- Thromboangiitis Obliterans (Buerger's Disease): A Young Woman's Rare Case and Current Knowledge.The International journal of angiology : official publication of the International College of Angiology, Inc · 2026Article
- Clinical outcomes of critical limb ischemia in Buerger disease: A contemporary analysis from an academic referral center in Jordan.PloS one · 2026Article
- Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathways.Frontiers in pharmacology · 2022Article
- Review
- Successful sequential drug eluting balloon angioplasty to chronic total occluded popliteal artery in a patient with thromboangitis obliterans by PCR.Anatolian journal of cardiology · 2016Article
- Thromboangiitis obliterans (Buerger's disease).Annals of medicine and surgery (2012) · 2016Review
- Buerger's disease: providing integrated care.Journal of multidisciplinary healthcare · 2016Review
- Critical limb ischemia in a young man: saddle embolism or unusual presentation of thromboangiitis obliterans?Case reports in vascular medicine · 2013Article
- Thromboangiitis Obliterans (Buerger's Disease)-Current Practices.International journal of inflammation · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study assessed the effectiveness and safety of bosentan when administered to thromboangiitis obliterans (Buerger's disease) patients.
methodsA clinical pilot study was designed in which patients with ulcer and/or pain at rest were treated with bosentan p.o. at a dose of 62.5 mg twice daily during the first month, which was thereafter up-titrated to 125 mg twice daily. The study endpoints were clinical improvement rate, major or minor amputation rate, haemodynamic changes, changes in endothelial function and angiographic changes.
resultsSeven out of 12 patients were male (58%). Median age was 39 years (range 29-49). The median follow-up was 20 months (range 11-40). All patients were smokers. With bosentan treatment, new ischaemic lesions were observed in only one patient. Overall, clinical improvement was observed in 12 of the 13 extremities (92%). Only two out of 13 extremities underwent amputation (one major and one minor) after bosentan treatment. After being assessed by digital arteriography with subtraction or angio-magnetic resonance imaging, an increase of distal flow was observed in 10 out of the 12 patients. All patients experienced a statistically significant improvement in their BAFMD values (mean: 1.8 at baseline; 6.6 at the end of the treatment; 12.7 three months after the end of the treatment; p < 0.01).
conclusionBosentan treatment may result in an improvement of clinical, angiographic and endothelial function outcomes. Bosentan should be investigated further in the management of TAO patients. Larger studies are required to confirm these results.
trial registrationClinicalTrials.gov: NCT01447550.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.